Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

Core Viewpoint - Zealand Pharma strengthens its leadership in innovation for obesity and related conditions with the appointment of Steven Johnson as Chief Development Officer [2][4] Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of innovative peptide-based medicines, with more than 10 drug candidates in clinical development, including two that have reached the market and three in late-stage development [5][6] Leadership Appointment - Steven Johnson brings nearly 30 years of experience in drug development and regulatory strategy, previously serving at UCB Biopharma and holding senior roles at Medpace, Inc. and Novo Nordisk [3][4] - His role will involve leading regulatory and development strategies, enhancing the company's R&D leadership alongside CMO David Kendall and CSO Utpal Singh [4][7] Strategic Focus - The appointment comes as Zealand Pharma collaborates with Roche to co-develop and co-commercialize petrelintide, aimed at addressing obesity and related complications [4][7] - The leadership team aims to align human-centered innovation with world-class science to develop new therapies that could redefine the standard of care for obesity [4]